Clinical Trial Update: A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AT9283 in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AT9283 (AT9283)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED